Loading...
healthfitnessmedicine
Cast your vote! Nivolumab vs. Brentuximab for Classical Hodgkin Lymphoma
About this Episode
In this episode, Bernie and Anthony are joined by two special guest expert hematologists:
Dr. David Russler-Germain
Dr. Tycel Phillips
We discuss recent updates in the treatment of upfront Classical Hodgkin Lymphoma, including whether the SWOG S1826 and HD21 trials change practice! Will it be a landslide victory for nivolumab? Is brentuximab fired?
Stay tuned to find out!
No transcript available for this episode.
